Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells

Cai, Hongqiao; Yang, Yang; Peng, Fenghui; Liu, Yahui; Fu, Xueqi; Bai, Jing

doi:10.7150/ijms.37427

Cited by 27 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miRNA is involved in cell regulation, including cell metabolism, cell proliferation, cell apoptosis, differentiation, and cell response, after virus infection [ 40 ]. Cai et al [ 41 ] demonstrated that sorafenib and AuNP–anti-miRNA-221 combination treatment exerts an anticancer effect on HCC via inhibiting miRNA-221/p27/DNMT1 signalling pathway. Lu et al [ 42 ] uncovered the interaction between FLJ33360 and miRNA-140.…”

Section: Discussionmentioning

confidence: 99%

Effects of miRNA-140 on the Growth and Clinical Prognosis of SMMC-7721 Hepatocellular Carcinoma Cell Line

Kong

Chen

Qiu

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Background. A growing number of studies have suggested that microRNAs exert an essential role in the development and occurrence of multiple tumours and act as crucial regulators in various biological processes. However, the expression and function of miRNA-140 in hepatocellular carcinoma (HCC) cells are not yet adequately identified and manifested. Methods. The expression of miRNA-140 was determined in HCC tissues and adjacent nontumour tissues by quantitative real-time polymerase chain reaction (qRT-PCR). Kaplan–Meier survival analysis and Cox regression analysis were performed to explore the correlation between miRNA-140 expression level and the survival rate of patients with HCC. Additionally, overexpression experiments were conducted to investigate the biological role of miRNA-140 in HCC cells. Bioinformatics was used to predict the related target genes and pathways of miRNA-140. Results. QRT-PCR results signified that the expression level of miRNA-140 in HCC was lower than that of adjacent normal tissues ( P < 0.0001 ). Compared with the control group, the SMMC-7721 HCC cells in the miRNA-140 mimic group had a decrease in proliferation, migration, and invasion ( P < 0.05 ), whereas those in the miRNA-140 inhibitor group had an increase in proliferation, migration, and invasion ( P < 0.05 ). Cell cycle arrest occurred in the G0/1 phase. Prognosis analysis showed that the expression level of miRNA-140 was not related to the prognosis of HCC. Furthermore, the Kaplan–Meier test revealed that patients with lower miRNA-140 expression levels in liver cancer tissue had significantly shorter disease-free survival (DFS, P = 0.004 ) and overall survival (OS) times ( P = 0.010 ) after hepatectomy. Cox regression analysis further indicated that miRNA-140 was an independent risk factor that may affect the DFS ( P = 0.004 ) and OS times ( P = 0.014 ) of patients after hepatectomy. Our results suggested that miRNA-140 might be a crucial regulator involved in the HCC progression and is thus considered a potential prognostic biomarker and therapeutic target for HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of miRNA-140 on the Growth and Clinical Prognosis of SMMC-7721 Hepatocellular Carcinoma Cell Line

Kong

Chen

Qiu

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…New data obtained from some patients with HCC in clinical trials suggest that miR221 plays a role in promoting tumorigenesis in HCC by inhibiting the expression of p27 154 . Cai et al investigated the synergistic inhibition of HCC cell proliferation by the combination of SOR and anti-miR221 conjugated to gold NPs 155 . The miRNA therapy increased the inhibitory effect of SOR on cell proliferation by inhibiting the miR221/p27/DNMTI signaling pathway.…”

Section: Combining Sor With Other Treatments For Synergistic Theramentioning

confidence: 99%

Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma

et al. 2021

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and one of the leading causes of cancer-related death worldwide. Advanced HCC displays strong resistance to chemotherapy, and traditional chemotherapy drugs do not achieve satisfactory therapeutic efficacy. Sorafenib is an oral kinase inhibitor that inhibits tumor cell proliferation and angiogenesis and induces cancer cell apoptosis. It also improves the survival rates of patients with advanced liver cancer. However, due to its poor solubility, fast metabolism, and low bioavailability, clinical applications of sorafenib have been substantially restricted. In recent years, various studies have been conducted on the use of nanoparticles to improve drug targeting and therapeutic efficacy in HCC. Moreover, nanoparticles have been extensively explored to improve the therapeutic efficacy of sorafenib, and a variety of nanoparticles, such as polymer, lipid, silica, and metal nanoparticles, have been developed for treating liver cancer. All these new technologies have improved the targeted treatment of HCC by sorafenib and promoted nanomedicines as treatments for HCC. This review provides an overview of hot topics in tumor nanoscience and the latest status of treatments for HCC. It further introduces the current research status of nanoparticle drug delivery systems for treatment of HCC with sorafenib.

show abstract

“…Likewise, gold nanoparticles loaded with anti-miR-221 were used to deliver the anti-miR to HCC cells in vitro. Using these nanoparticles, it was also found that anti-miR-221 could enhance the sensitivity of HCC cells to sorafenib [ 110 ]. Another notable strategy to address the issue with miRNA delivery has been the modification of miRNA itself [ 26 , 30 , 119 ].…”

Section: The Role Of Mirnas In Developing Therapeutics Targeting Gmentioning

confidence: 99%

Roles of microRNAs in Gastrointestinal Cancer Stem Cell Resistance and Therapeutic Development

Hwang

Yuen

2021

IJMS

View full text Add to dashboard Cite

Resistance to cancer treatment is one of the major challenges currently faced when treating gastrointestinal (GI) cancers. A major contributing factor to this resistance is the presence of cancer stem cells (CSCs) in GI cancers (e.g., colorectal, pancreatic, gastric, liver cancer). Non-coding RNAs, such as microRNAs (miRNAs), have been found to regulate several key targets that are responsible for cancer stemness, and function as oncogenic miRNAs (oncomiRs) or tumor suppressor miRNAs. As a result, several miRNAs have been found to alter, or be altered by, the expression of CSC-defining markers and their related pathways. These miRNAs can be utilized to affect stemness in multiple ways, including directly targeting CSCs and enhancing the efficacy of cancer therapeutics. This review highlights current studies regarding the roles of miRNAs in GI CSCs, and efforts towards the development of cancer therapeutics.

show abstract

Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells

Cited by 27 publications

References 32 publications

Effects of miRNA-140 on the Growth and Clinical Prognosis of SMMC-7721 Hepatocellular Carcinoma Cell Line

Effects of miRNA-140 on the Growth and Clinical Prognosis of SMMC-7721 Hepatocellular Carcinoma Cell Line

Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma

Roles of microRNAs in Gastrointestinal Cancer Stem Cell Resistance and Therapeutic Development

Contact Info

Product

Resources

About